Histone methyltransferases in cancer

Seminars in Cell and Developmental Biology

Volumn 21, Issue 2, 2010, Pages 209-220

  Albert, Mareike ^a   Helin, Kristian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Epigenetics; Histone methyltransferase; Polycomb group protein; Transcription

Indexed keywords

CELL NUCLEUS RECEPTOR; HISTONE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; POLYCOMB GROUP PROTEIN;

EPIGENETICS; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; PHYLOGENETIC TREE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 77049099785     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2009.10.007     Document Type: Review

References (169)

1. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 4 (2007) 683-692
2. Sparmann A., and van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6 11 (2006) 846-856
3. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37 4 (2005) 391-400
4. Weber M., Davies J.J., Wittig D., Oakeley E.J., Haase M., Lam W.L., et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37 8 (2005) 853-862
5. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 6 (2002) 415-428
6. Jain N., Rossi A., and Garcia-Manero G. Epigenetic therapy of leukemia: an update. Int J Biochem Cell Biol 41 1 (2009) 72-80
7. Smith L.T., Otterson G.A., and Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet 23 9 (2007) 449-456
8. Bedford M.T., and Clarke S.G. Protein arginine methylation in mammals: who, what, and why. Mol Cell 33 1 (2009) 1-13
9. Hublitz P., Albert M., and Peters A.H. Mechanisms of transcriptional repression by histone lysine methylation. Int J Dev Biol 53 2-3 (2009) 335-354
10. Martin C., and Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 6 11 (2005) 838-849
11. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., et al. High-resolution profiling of histone methylations in the human genome. Cell 129 4 (2007) 823-837
12. Agger K., Christensen J., Cloos P.A., and Helin K. The emerging functions of histone demethylases. Curr Opin Genet Dev 18 2 (2008) 159-168
13. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., and Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22 20 (2003) 5323-5335
14. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 6907 (2002) 624-629
15. Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A., et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12 4 (2006) 1168-1174
16. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100 20 (2003) 11606-11611
17. Weikert S., Christoph F., Kollermann J., Muller M., Schrader M., Miller K., et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16 2 (2005) 349-353
18. Kassambara A., Klein B., and Moreaux J. MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem Biophys Res Commun 379 4 (2009) 840-845
19. Chadwick R.B., Jiang G.L., Bennington G.A., Yuan B., Johnson C.K., Stevens M.W., et al. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci USA 97 6 (2000) 2662-2667
20. Fang W., Piao Z., Buyse I.M., Simon D., Sheu J.C., Perucho M., et al. Preferential loss of a polymorphic RIZ allele in human hepatocellular carcinoma. Br J Cancer 84 6 (2001) 743-747
21. Tam W., Gomez M., Chadburn A., Lee J.W., Chan W.C., and Knowles D.M. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 107 10 (2006) 4090-4100
22. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 5797 (2006) 268-274
23. Rahman N. Mechanisms predisposing to childhood overgrowth and cancer. Curr Opin Genet Dev 15 3 (2005) 227-233
24. Tatton-Brown K., Douglas J., Coleman K., Baujat G., Cole T.R., Das S., et al. Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. Am J Hum Genet 77 2 (2005) 193-204
25. Kolomietz E., Marrano P., Yee K., Thai B., Braude I., Kolomietz A., et al. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia 17 7 (2003) 1313-1323
26. Skawran B., Steinemann D., Weigmann A., Flemming P., Becker T., Flik J., et al. Gene expression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions. Mod Pathol 21 5 (2008) 505-516
27. Kleefstra T., Smidt M., Banning M.J., Oudakker A.R., Van Esch H., de Brouwer A.P., et al. Disruption of the gene Euchromatin Histone Methyl Transferase1 (Eu-HMTase1) is associated with the 9q34 subtelomeric deletion syndrome. J Med Genet 42 4 (2005) 299-306
28. Angrand P.O., Apiou F., Stewart A.F., Dutrillaux B., Losson R., and Chambon P. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 74 1 (2001) 79-88
29. Krivtsov A.V., and Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7 11 (2007) 823-833
30. Cerveira N., Correia C., Doria S., Bizarro S., Rocha P., Gomes P., et al. Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. Leukemia 17 11 (2003) 2244-2247
31. La Starza R., Gorello P., Rosati R., Riezzo A., Veronese A., Ferrazzi E., et al. Cryptic insertion producing two NUP98/NSD1 chimeric transcripts in adult refractory anemia with an excess of blasts. Genes Chromosomes Cancer 41 4 (2004) 395-399
32. Rosati R., La Starza R., Veronese A., Aventin A., Schwienbacher C., Vallespi T., et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 99 10 (2002) 3857-3860
33. Chesi M., Nardini E., Lim R.S., Smith K.D., Kuehl W.M., and Bergsagel P.L. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92 9 (1998) 3025-3034
34. Du Y., Carling T., Fang W., Piao Z., Sheu J.C., and Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res 61 22 (2001) 8094-8099
35. Lal G., Padmanabha L., Smith B.J., Nicholson R.M., Howe J.R., O'Dorisio M.S., et al. RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma. Cancer 107 12 (2006) 2752-2759
36. Piao G.H., Piao W.H., He Y., Zhang H.H., Wang G.Q., and Piao Z. Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma. Histol Histopathol 23 10 (2008) 1171-1175
37. Deng Q., and Huang S. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene 23 28 (2004) 4903-4910
38. Watanabe Y., Toyota M., Kondo Y., Suzuki H., Imai T., Ohe-Toyota M., et al. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 13 16 (2007) 4786-4794
39. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322 5908 (2008) 1695-1699
40. Nie K., Gomez M., Landgraf P., Garcia J.F., Liu Y., Tan L.H., et al. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol 173 1 (2008) 242-252
41. Courts C., Montesinos-Rongen M., Brunn A., Bug S., Siemer D., Hans V., et al. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol 67 7 (2008) 720-727
42. Pasqualucci L., Compagno M., Houldsworth J., Monti S., Grunn A., Nandula S.V., et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203 2 (2006) 311-317
43. D'Costa K., Emslie D., Metcalf D., Smyth G.K., Karnowski A., Kallies A., et al. Blimp1 is limiting for transformation in a mouse plasmacytoma model. Blood (2009)
44. Zhao W.L., Liu Y.Y., Zhang Q.L., Wang L., Leboeuf C., Zhang Y.W., et al. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 111 7 (2008) 3867-3871
45. Oda H., Okamoto I., Murphy N., Chu J., Price S.M., Shen M.M., et al. Monomethylation of histone H4-lysine 20 is involved in chromosome structure and stability and is essential for mouse development. Mol Cell Biol 29 8 (2009) 2278-2295
46. Peters A.H., O'Carroll D., Scherthan H., Mechtler K., Sauer S., Schofer C., et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107 3 (2001) 323-337
47. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., et al. Induction of tumors in mice by genomic hypomethylation. Science 300 5618 (2003) 489-492
48. Yagi H., Deguchi K., Aono A., Tani Y., Kishimoto T., and Komori T. Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood 92 1 (1998) 108-117
49. Yu B.D., Hess J.L., Horning S.E., Brown G.A., and Korsmeyer S.J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378 6556 (1995) 505-508
50. Terranova R., Agherbi H., Boned A., Meresse S., and Djabali M. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci USA 103 17 (2006) 6629-6634
51. McMahon K.A., Hiew S.Y., Hadjur S., Veiga-Fernandes H., Menzel U., Price A.J., et al. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 1 3 (2007) 338-345
52. Bach C., Mueller D., Buhl S., Garcia-Cuellar M.P., and Slany R.K. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene 28 6 (2009) 815-823
53. Sauvageau G., Lansdorp P.M., Eaves C.J., Hogge D.E., Dragowska W.H., Reid D.S., et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci USA 91 25 (1994) 12223-12227
54. Thorsteinsdottir U., Mamo A., Kroon E., Jerome L., Bijl J., Lawrence H.J., et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99 1 (2002) 121-129
55. Li Z., Luo R.T., Mi S., Sun M., Chen P., Bao J., et al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res 69 3 (2009) 1109-1116
56. Afonja O., Smith Jr. J.E., Cheng D.M., Goldenberg A.S., Amorosi E., Shimamoto T., et al. MEIS1 and HOXA7 genes in human acute myeloid leukemia. Leuk Res 24 10 (2000) 849-855
57. Lawrence H.J., Rozenfeld S., Cruz C., Matsukuma K., Kwong A., Komuves L., et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 13 12 (1999) 1993-1999
58. Ayton P.M., and Cleary M.L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17 18 (2003) 2298-2307
59. Kroon E., Krosl J., Thorsteinsdottir U., Baban S., Buchberg A.M., and Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17 13 (1998) 3714-3725
60. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., et al. hDOT1L links histone methylation to leukemogenesis. Cell 121 2 (2005) 167-178
61. Okada Y., Jiang Q., Lemieux M., Jeannotte L., Su L., and Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 8 9 (2006) 1017-1024
62. Tebar F., Bohlander S.K., and Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 10 8 (1999) 2687-2702
63. Lin Y.H., Kakadia P.M., Chen Y., Li Y.Q., Deshpande A.J., Buske C., et al. Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10 positive leukemias. Blood (2009)
64. Caudell D., Zhang Z., Chung Y.J., and Aplan P.D. Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res 67 17 (2007) 8022-8031
65. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14 5 (2008) 355-368
66. Mueller D., Bach C., Zeisig D., Garcia-Cuellar M.P., Monroe S., Sreekumar A., et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110 13 (2007) 4445-4454
67. Zeisig D.T., Bittner C.B., Zeisig B.B., Garcia-Cuellar M.P., Hess J.L., and Slany R.K. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 24 35 (2005) 5525-5532
68. Wang G.G., Cai L., Pasillas M.P., and Kamps M.P. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 9 7 (2007) 804-812
69. Wang G.G., Song J., Wang Z., Dormann H.L., Casadio F., Li H., et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature (2009)
70. Cheung N., Chan L.C., Thompson A., Cleary M.L., and So C.W. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 9 10 (2007) 1208-1215
71. Whitman S.P., Liu S., Vukosavljevic T., Rush L.J., Yu L., Liu C., et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 106 1 (2005) 345-352
72. Dorrance A.M., Liu S., Chong A., Pulley B., Nemer D., Guimond M., et al. The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. Blood 112 6 (2008) 2508-2511
73. Dorrance A.M., Liu S., Yuan W., Becknell B., Arnoczky K.J., Guimond M., et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest 116 10 (2006) 2707-2716
74. Cloos P.A., Christensen J., Agger K., and Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev 22 9 (2008) 1115-1140
75. Krogan N.J., Kim M., Tong A., Golshani A., Cagney G., Canadien V., et al. Methylation of histone H3 by Set2 in Saccharomyces cerevisae is linked to transcriptional elongation by RNA polymerase II. Mol Cell Biol 23 12 (2003) 4207-4218
76. Li B., Howe L., Anderson S., Yates III J.R., and Workman J.L. The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II. J Biol Chem 278 11 (2003) 8897-8903
77. Strahl B.D., Grant P.A., Briggs S.D., Sun Z.W., Bone J.R., Caldwell J.A., et al. Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. Mol Cell Biol 22 5 (2002) 1298-1306
78. Xiao T., Hall H., Kizer K.O., Shibata Y., Hall M.C., Borchers C.H., et al. Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast. Genes Dev 17 5 (2003) 654-663
79. Nimura K., Ura K., Shiratori H., Ikawa M., Okabe M., Schwartz R.J., et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 460 7252 (2009) 287-291
80. Rayasam G.V., Wendling O., Angrand P.O., Mark M., Niederreither K., Song L., et al. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J 22 12 (2003) 3153-3163
81. Huang N., vom Baur E., Garnier J.M., Lerouge T., Vonesch J.L., Lutz Y., et al. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J 17 12 (1998) 3398-3412
82. Jaju R.J., Fidler C., Haas O.A., Strickson A.J., Watkins F., Clark K., et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15. 5) in de novo childhood acute myeloid leukemia. Blood 98 4 (2001) 1264-1267
83. Kurotaki N., Imaizumi K., Harada N., Masuno M., Kondoh T., Nagai T., et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 30 4 (2002) 365-366
84. Keats J.J., Maxwell C.A., Taylor B.J., Hendzel M.J., Chesi M., Bergsagel P.L., et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 105 10 (2005) 4060-4069
85. Moreau P., Facon T., Leleu X., Morineau N., Huyghe P., Harousseau J.L., et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100 5 (2002) 1579-1583
86. Santra M., Zhan F., Tian E., Barlogie B., and Shaughnessy Jr. J. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101 6 (2003) 2374-2376
87. Stec I., Wright T.J., van Ommen G.J., de Boer P.A., van Haeringen A., Moorman A.F., et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 7 7 (1998) 1071-1082
88. Lauring J., Abukhdeir A.M., Konishi H., Garay J.P., Gustin J.P., Wang Q., et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 111 2 (2008) 856-864
89. Marango J., Shimoyama M., Nishio H., Meyer J.A., Min D.J., Sirulnik A., et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111 6 (2008) 3145-3154
90. Brito J.L., Walker B., Jenner M., Dickens N.J., Brown N.J., Ross F.M., et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 94 1 (2009) 78-86
91. Kim J.Y., Kee H.J., Choe N.W., Kim S.M., Eom G.H., Baek H.J., et al. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol 28 6 (2008) 2023-2034
92. Taketani T., Taki T., Nakamura H., Taniwaki M., Masuda J., and Hayashi Y. NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes. Cancer Genet Cytogenet 190 2 (2009) 108-112
93. Ringrose L., and Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 38 (2004) 413-443
94. Levine S.S., King I.F., and Kingston R.E. Division of labor in polycomb group repression. Trends Biochem Sci 29 9 (2004) 478-485
95. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24 2 (2006) 268-273
96. Koontz J.I., Soreng A.L., Nucci M., Kuo F.C., Pauwels P., van Den Berghe H., et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 98 11 (2001) 6348-6353
97. Li H., Ma X., Wang J., Koontz J., Nucci M., and Sklar J. Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival. Proc Natl Acad Sci USA 104 50 (2007) 20001-20006
98. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41 5 (2009) 521-523
99. Friedman J.M., Liang G., Liu C.C., Wolff E.M., Tsai Y.C., Ye W., et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69 6 (2009) 2623-2629
100. Sander S., Bullinger L., Klapproth K., Fiedler K., Kestler H.A., Barth T.F., et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112 10 (2008) 4202-4212
101. Croonquist P.A., and Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24 41 (2005) 6269-6280
102. Gil J., and Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7 9 (2006) 667-677
103. Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D., Gargiulo G., Beekman C., et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 21 5 (2007) 525-530
104. Haupt Y., Alexander W.S., Barri G., Klinken S.P., and Adams J.M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 65 5 (1991) 753-763
105. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., and Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65 5 (1991) 737-752
106. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., and van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13 20 (1999) 2678-2690
107. Bruggeman S.W., Valk-Lingbeek M.E., van der Stoop P.P., Jacobs J.J., Kieboom K., Tanger E., et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 19 12 (2005) 1438-1443
108. van der Lugt N.M., Domen J., Linders K., van Roon M., Robanus-Maandag E., te Riele H., et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 8 7 (1994) 757-769
109. Molofsky A.V., He S., Bydon M., Morrison S.J., and Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 19 12 (2005) 1432-1437
110. Molofsky A.V., Pardal R., Iwashita T., Park I.K., Clarke M.F., and Morrison S.J. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425 6961 (2003) 962-967
111. Dietrich N., Bracken A.P., Trinh E., Schjerling C.K., Koseki H., Rappsilber J., et al. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J 26 6 (2007) 1637-1648
112. Gil J., Bernard D., Martinez D., and Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 6 1 (2004) 67-72
113. Bernard D., Martinez-Leal J.F., Rizzo S., Martinez D., Hudson D., Visakorpi T., et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 24 36 (2005) 5543-5551
114. Cao Q., Yu J., Dhanasekaran S.M., Kim J.H., Mani R.S., Tomlins S.A., et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27 58 (2008) 7274-7284
115. Fujii S., and Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 99 4 (2008) 738-746
116. Herranz N., Pasini D., Diaz V.M., Franci C., Gutierrez A., Dave N., et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 28 15 (2008) 4772-4781
117. Morey L., Brenner C., Fazi F., Villa R., Gutierrez A., Buschbeck M., et al. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol 28 19 (2008) 5912-5923
118. Villa R., Pasini D., Gutierrez A., Morey L., Occhionorelli M., Vire E., et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11 6 (2007) 513-525
119. Boukarabila H., Saurin A.J., Batsche E., Mossadegh N., van Lohuizen M., Otte A.P., et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 23 10 (2009) 1195-1206
120. Yu J., Cao Q., Mehra R., Laxman B., Tomlins S.A., Creighton C.J., et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12 5 (2007) 419-431
121. Lee J., Son M.J., Woolard K., Donin N.M., Li A., Cheng C.H., et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13 1 (2008) 69-80
122. Chamberlain S.J., Yee D., and Magnuson T. Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells 26 6 (2008) 1496-1505
123. Pasini D., Bracken A.P., Hansen J.B., Capillo M., and Helin K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol 27 10 (2007) 3769-3779
124. Shen X., Liu Y., Hsu Y.J., Fujiwara Y., Kim J., Mao X., et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 32 4 (2008) 491-502
125. Beke L., Nuytten M., Van Eynde A., Beullens M., and Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 26 31 (2007) 4590-4595
126. Yang X., Karuturi R.K., Sun F., Aau M., Yu K., Shao R., et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE 4 4 (2009) e5011
127. O'Carroll D., Erhardt S., Pagani M., Barton S.C., Surani M.A., and Jenuwein T. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 21 13 (2001) 4330-4336
128. Liu J., Cao L., Chen J., Song S., Lee I.H., Quijano C., et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 459 7245 (2009) 387-392
129. Zeisig B.B., Cheung N., Yeung J., and So C.W. Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia. Cancer Cell 14 5 (2008) 345-347
130. Greiner D., Bonaldi T., Eskeland R., Roemer E., and Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 1 3 (2005) 143-145
131. Kubicek S., O'Sullivan R.J., August E.M., Hickey E.R., Zhang Q., Teodoro M.L., et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25 3 (2007) 473-481
132. Miranda T.B., Cortez C.C., Yoo C.B., Liang G., Abe M., Kelly T.K., et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8 6 (2009) 1579-1588
133. Tan J., Yang X., Zhuang L., Jiang X., Chen W., Lee P.L., et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21 9 (2007) 1050-1063
134. Schultz J., Milpetz F., Bork P., and Ponting C.P. SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci USA 95 11 (1998) 5857-5864
135. Whitman S.P., Hackanson B., Liyanarachchi S., Liu S., Rush L.J., Maharry K., et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 112 5 (2008) 2013-2016
136. Saigo K., Yoshida K., Ikeda R., Sakamoto Y., Murakami Y., Urashima T., et al. Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma. Hum Mutat 29 5 (2008) 703-708
137. Van Vlierberghe P., van Grotel M., Tchinda J., Lee C., Beverloo H.B., van der Spek P.J., et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 111 9 (2008) 4668-4680
138. Arisan S., Buyuktuncer E.D., Palavan-Unsal N., Caskurlu T., Cakir O.O., and Ergenekon E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75 3 (2005) 252-257
139. Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., and Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11 24 Pt 1 (2005) 8570-8576
140. Mimori K., Ogawa K., Okamoto M., Sudo T., Inoue H., and Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 31 4 (2005) 376-380
141. Sudo T., Utsunomiya T., Mimori K., Nagahara H., Ogawa K., Inoue H., et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92 9 (2005) 1754-1758
142. van Kemenade F.J., Raaphorst F.M., Blokzijl T., Fieret E., Hamer K.M., Satijn D.P., et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97 12 (2001) 3896-3901
143. Visser H.P., Gunster M.J., Kluin-Nelemans H.C., Menders E.M., Raaphorst F.M., Meijer C.J., et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 112 4 (2001) 950-958
144. Douglas J., Hanks S., Temple I.K., Davies S., Murray A., Upadhyaya M., et al. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am J Hum Genet 72 1 (2003) 132-143
145. Tatton-Brown K., and Rahman N. Sotos syndrome. Eur J Hum Genet 15 3 (2007) 264-271
146. Li J., Yin C., Okamoto H., Mushlin H., Balgley B.M., Lee C.S., et al. Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro Oncol 10 1 (2008) 45-51
147. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61 5 (2001) 2129-2137
148. Kleefstra T., Brunner H.G., Amiel J., Oudakker A.R., Nillesen W.M., Magee A., et al. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am J Hum Genet 79 2 (2006) 370-377
149. Kleefstra T., van Zelst-Stams W.A., Nillesen W.M., Cormier-Daire V., Houge G., Foulds N., et al. Further clinical and molecular delineation of the 9q Subtelomeric Deletion Syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet (2009)
150. Yatsenko S.A., Brundage E.K., Roney E.K., Cheung S.W., Chinault A.C., and Lupski J.R. Molecular mechanisms for subtelomeric rearrangements associated with the 9q34.3 microdeletion syndrome. Hum Mol Genet (2009)
151. Northcott P.A., Nakahara Y., Wu X., Feuk L., Ellison D.W., Croul S., et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41 4 (2009) 465-472
152. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A., et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci USA 103 50 (2006) 19176-19181
153. Hamamoto R., Silva F.P., Tsuge M., Nishidate T., Katagiri T., Nakamura Y., et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97 2 (2006) 113-118
154. Tsuge M., Hamamoto R., Silva F.P., Ohnishi Y., Chayama K., Kamatani N., et al. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet 37 10 (2005) 1104-1107
155. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6 8 (2004) 731-740
156. Hu L., Zhu Y.T., Qi C., and Zhu Y.J. Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Res (2009)
157. He L., Yu J.X., Liu L., Buyse I.M., Wang M.S., Yang Q.C., et al. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res 58 19 (1998) 4238-4244
158. Steele-Perkins G., Fang W., Yang X.H., Van Gele M., Carling T., Gu J., et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 15 17 (2001) 2250-2262
159. Oshimo Y., Oue N., Mitani Y., Nakayama H., Kitadai Y., Yoshida K., et al. Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer 110 2 (2004) 212-218
160. Jiang G., Liu L., Buyse I.M., Simon D., and Huang S. Decreased RIZ1 expression but not RIZ2 in hepatoma and suppression of hepatoma tumorigenicity by RIZ1. Int J Cancer 83 4 (1999) 541-546
161. Reid A.G., and Nacheva E.P. A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion. Leukemia 18 1 (2004) 178-180
162. Nishikawa N., Toyota M., Suzuki H., Honma T., Fujikane T., Ohmura T., et al. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 67 20 (2007) 9649-9657
163. Goulet I., Gauvin G., Boisvenue S., and Cote J. Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J Biol Chem 282 45 (2007) 33009-33021
164. El Messaoudi S., Fabbrizio E., Rodriguez C., Chuchana P., Fauquier L., Cheng D., et al. Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci USA 103 36 (2006) 13351-13356
165. Hong H., Kao C., Jeng M.H., Eble J.N., Koch M.O., Gardner T.A., et al. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 101 1 (2004) 83-89
166. Majumder S., Liu Y., Ford III O.H., Mohler J.L., and Whang Y.E. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate 66 12 (2006) 1292-1301
167. Pal S., Baiocchi R.A., Byrd J.C., Grever M.R., Jacob S.T., and Sif S. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J 26 15 (2007) 3558-3569
168. Wang L., Pal S., and Sif S. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol 28 20 (2008) 6262-6277
169. Bracken A.P., and Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 9 11 (2009) 773-784